[Ip-health] Civil Society statement supporting Proposal by Dutch to evaluate IP and incentives for medical innovation

Sophie Bloemen sophie at commonsnetwork.eu
Fri Jun 3 00:52:05 PDT 2016


http://commonsnetwork.eu/wp-content/uploads/2016/06/Civil-Society-Statement-IPR-in-CC-.pdf

*Civil Society 
<http://commonsnetwork.eu/wp-content/uploads/2016/06/Civil-Society-Statement-IPR-in-CC-.pdf> urge**s 
Member States to defend the need for a critical review of the 
intellectual property system and incentives for medical innovation*

June 2nd 2016, BRUSSELS
The signing Civil Society organisations call on Member States to resist 
pressure from the pharmaceutical industry to eliminate critical elements 
of proposed European Union (EU) Council Conclusions that would improve 
the balance between innovation and patients’ access to affordable 
medicines. These Conclusions are scheduled for adoption by the Council 
on June 17, 2016.

The Dutch EU Presidency has proposed an evaluation of EU mechanisms to 
encourage innovation for medicines. It now appears that specific 
recommendations that examine the suitability and impact of excessive 
intellectual property protection may be removed.

A coalition of public health organisations calls on Member States to 
support the latest Presidency’s proposal, dated May 24 and, in 
particular, Articles 38-41 (“regarding market and data exclusivity, the 
use of supplementary protection certificates, the scope of the patent 
“Bolar” and research patent exemption and other relevant instruments for 
intellectual property protection, in particular also regarding the 
orphan medicinal products regulation”).

Excessive and additional Intellectual Property Rights (IPR) do not 
contribute to genuine needs-driven medical innovation, and also delay 
generic competition, which results in unaffordable medicines prices that 
European health care systems struggle with today. It is an issue 
requiring urgent political action.

As outlined in Article 39 of the latest draft of the aforementioned 
Council Conclusions, it is of utmost importance that the European 
Commission conducts an in-depth independent evaluation of the impact of 
the IP-related incentives on medical innovation and affordability of 
treatments.

On June 17, EU Health Ministers should sign off meaningful Council 
Conclusions and not allow narrow commercial and political interests 
undermine public health needs. We call on our representatives to 
consider their citizens, the future of health systems, and the general 
public interest.

See also,civil society statement of April 18, 2016. 
<http://commonsnetwork.eu/civil-society-urges-member-states-to-support-the-dutch-eu-presidencys-vision-on-access-to-affordable-medicines/>

Signed by:

1. AIDES, France

2. ARAS – Asociatia Romana Anti-SIDA

3. Berne Declaration

4. BUKO Pharma-Kampagne (Germany)

5. Coalition PLUS: Coalition Internationale Sida

6. Commons Network

7. EKPIZO – Greek Consumer Association “Quality of Life”

8. European AIDS Treatment Group 9. European Public Health Alliance (EPHA)

10. Global Health Advocates (GHA)

11. Health Action International (HAI)

12. Health Projects for Latvia

13. International Society of Drug Bulletins (ISDB)

14. Knowledge Ecology International (KEI) Europe

15. Médecins du monde – Doctors of the World International Network

16. Médecins Sans Frontières – Access Campaign

17. Medicines in Europe Forum (MiEF)

18. No Gracias (Spain)

19. PRAKSIS (Greece)

20. Salud por Derecho (Spain)

21. STOPAIDS (UK)

22. Transparency International, Pharmaceuticals & Healthcare Programme

23. Ukrainian Network of People Living with HIV/AIDS

24. Universities Allied for Essential Medicines – Europe

25. WEMOS Foundation


-- 
Sophie Bloemen
Commons Network
Kyffäuserstr.4
10781 Berlin
Tel: 0049 170 2827005
www.commonsnetwork.eu
twitter: @sbloemen




More information about the Ip-health mailing list